Development of the international network to supply HPV vaccine internationally

At the same time, the introduction of the new product, such as the HPV therapeutic vaccine needs the development of the network, which can maximize the effectiveness of the distribution of the HPV therapeutic vaccine. In this regard, it is worth mentioning the fact that the company can meet the high demand on the vaccine, which can be traced in the contemporary health care environment. As the matter of fact, the well-developed, extensive network will allow the company to supply the product to health care organizations and customers fast and en masse. As a result, business interests of the pharma company developing the HPV therapeutic vaccine will meet needs and interests of health care system and patients.
Furthermore, the development of the network will facilitate the introduction of the HPV therapeutic vaccine in new markets. In fact, the problem of HPV and the cervical cancer is an international problem because women suffer from the cervical cancer worldwide. As a result, the introduction of the new vaccine will help to tackle the problem of the prevention of such a serious disease as the cervical cancer. The more effective and widely-spread the network is the larger may be the market share of the company and the larger number of patients can receive the HPV therapeutic vaccine in time.

3.5 Expected economic effects after the successful introduction of HPV vaccine
Taking into consideration the scope of the problem of HPV and the cervical cancer, the introduction of the HPV therapeutic vaccine can provoke the high demand on the vaccine. In this respect, it is worth mentioning the fact that the company introducing the HPV therapeutic vaccine should assess adequately its production facilities and the ability to supply the vaccine in the market to meet the demand. The price of the product should not be exorbitant because the vaccine is often the matter of life and death of many patients. Therefore, the company can establish prices affordable for average consumers and increase the production facilities to meet the growing demand on the product.
At the same time, economic effects from the introduction of the HPV therapeutic vaccine are likely to be positive. In this regard, it is worth mentioning the fact that the company introducing the HPV therapeutic vaccine is likely to face the competition from the part of the GSK and Merck, which are rather substitutes than direct rivals to the HPV therapeutic vaccine. Consequently, the company can count for the leading position in the market. At the beginning the company can hold the leading position in the market. The revenues of the company can exceed 10% in first year after the introduction of the HPV therapeutic vaccine and reach 15% in the next 2-3 years. In fact, the revenues of the income will stay high as long as strong rivals appear in the market.

Conclusion
Thus, taking into account all above mentioned, it is important to place emphasis on the fact that the HPV therapeutic vaccine is essential and the vaccine has to be introduced in the contemporary health care system to help many patients and to prevent the development of the cervical cancer. At the same time, the HPV therapeutic vaccine has great prospects from the commercial point of view because it can bring considerable profits to the pharma company introducing the product and put it into the leading position in the market. On the other hand, the company should conduct ethically responsible policies to make the vaccine available to a large number of patients.

References:
Alam, Naveed et al 2005. “Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature.” Lung Cancer.47, No. 3, pp. 385-94.
Blayney, D. W. et al 2005. “Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin’s lymphoma.” The Oncologist. 10, No. 2 , pp. 138-49.
Cervical Cancer ”“ UK Incidence Statistics. 2010.
Demers, W. G. et al 2003. “Pharmacologic indicators of antitumor efficacy for oncolytic virotherapy.” Cancer Research. 63, No. 14, pp. 4003-8.
Human papillomaviruses World Health Organization, International Agency for Research on Cancer 2007.
“Human Papillomavirus and Genital Warts, NIAID Fact Sheet.” NIAID Health Matters. 14 Aug. 2006. National Institute of Allergy and Infectious Diseases; National Institutes of Health U.S. Department of Health and Human Services.
“Human Papilloma Infection (HPV).” Center for Disease Control and Prevention. 2009. Department of Health and Human Services.
“Important Information About Gardasil.” Gardasil. 2008. Merck & Co, Inc.
Stoppler, M. & Melissa, C. (2007). “Human Papillomaviruses (HPVs) and Genital Warts.” MedicineNet. Ed. Jay W. Marks, Md. MedicineNet, Inc.
Syrjanen, K., Parkkinen, S., Mantyjarvi, R., Vayrynen, M., Syrjanen, S., Holopainen, H., Saarikoski,S., Castren, O. (1985). “Human Papillomavirus (HPV) Type as an Important Determinant of the Natural History of HPV Infections in Uterine Cervix”.European Journal of Epidemiology, Vol. 1, No. 3, P. 180-187.
Yancey, DIane. (2002). STDs: What you Dont Know Can Hurt You.PP 73-86.Minneapolis: Twenty First Century Books.